With biologics dominating its pipeline, Sanofi will spend as much as $2 billion on its biologics manufacturing network over the next several years.

Novo Nordisk just took another step toward a potential kick-start for its newest basal insulin, Tresiba.

In the immuno-oncology rivalry between Merck’s Keytruda and BMS’ Opdivo, Keytruda has been running the table. But Opdivo boasts the latest win.

California lawmakers are weighing a bill that would cut off most drugmaker payments to physicians, including speaking fees for that staple of pharma marketing…

Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and…

Massachusetts-based Radius Health scored an early approval Friday for Tymlos, an osteoporosis treatment for postmenopausal women. But to succeed with the drug…

The FDA is ordering major label changes on pain meds codeine and tramadol that will affect dozens of companies.

Kim Kardashian is back on social media plugging for pharma. This time, the FDA might like her Instagram post better, but Instagram followers weren't so…

Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.

Pharma has come a long way on patient centricity. Regulators, though? Not so much, Treato's CEO says.

Regulatory